18 Chapter 1631

Total Page:16

File Type:pdf, Size:1020Kb

18 Chapter 1631 18 Gas chromatography S Dawling, S Jickells and A Negrusz Introduction . 469 Quantitative determinations . 505 Gas chromatography Optimising operation conditions to columns . 470 customise applications . 506 Inlet systems . 483 Specific applications. 508 Detector systems . 493 References . 510 Specimen preparation . 498 Further reading . 511 Introduction When a mixture of substances is injected at the inlet, each component partitions between the Gas chromatography (GC) is applicable to a wide stationary phase and the gas phase as it is swept range of compounds of interest to toxicologists, towards the detector. Molecules that have greater pharmaceutical and industrial chemists, envir- affinity for the stationary phase spend more time onmentalists and clinicians. Adsorption GC was in that phase and consequently take longer to developed by a German scientist, Fritz Prior, in reach the detector. The detector produces a the late 1940s. In the early 1950s Archer J. P. signal proportional to the amount of substance Martin and Richard L. M. Synge, two scientists that passes through it, and this signal is from the UK, invented partition chromatog- processed and fed to an integrator or some other raphy, for which they received the Nobel Prize in recording device. Each substance that elutes chemistry in 1952. This marks a true beginning from the column has a characteristic retention of GC as a broadly used analytical technique. If time, defined as the time interval from injection a compound has sufficient volatility for its mo- to peak detector response. Figure 18.1 shows a lecules to be in the gas or vapour phase at or schematic of a GC system. below 400ЊC, and does not decompose at these Identification of components was traditionally temperatures, then the compound can probably based primarily on peak retention time, but it is be analysed by GC. becoming increasingly more reliant on the The separation is performed in a column nature of the response obtained from the (containing either a solid or liquid stationary detector. The analyst has two main goals: firstly, phase) that has a continuous flow of mobile to make each different compound appear in a phase passing through it – usually an inert discrete band or peak with no overlap (or co- carrier gas, but more recently supercritical fluids elution) with other components in the mixture, (SCFs) have been used for some applications – and, secondly, to make these bands uniform in maintained in a temperature-regulated oven. shape and as narrow as possible. This is achieved 470 Clarke’s Analytical Forensic Toxicology Gas supply Injector CarrierMake up Detector Regulators and dryers Sample tray Detector Oven Instrument controller Data Data Column processor monitor Storage Figure 18.1 A modern GC system. partly by judicious choice of the column provided much higher resolution efficiencies stationary phase and its loading, and partly by and smaller peak volumes, which provoked optimising the operating conditions of the further modifications in detector design. The column. In addition, the method of introducing latest column developments mean that peaks of the sample into the chromatograph, the choice only a few milliseconds are a real possibility in of detector, and chemical modification to both GC and liquid chromatography (LC). Since improve the volatility of the compounds also this matches the response time of the current contribute to converting a mediocre analysis sensor electronics, the ingenuity of the detector into a first-class one. design engineers is again being tested. There has been a continuous synergism between enhanced detector performance and column performance, each advance being recip- Gas chromatography columns rocally dependent on the other. Initially, high- sensitivity detectors permitted the development of a precise column theory that, in turn, enabled Packed columns made of glass or steel contain a the design of columns that had much higher stationary phase (see below), either loaded efficiencies. The improved efficiency of columns directly into the column if it is a solid at its oper- resulted in substances eluting from the separa- ating temperature, or coated onto the surface of tion columns as very low volumes compared to a solid support if it is liquid at its operating the volume of the detectors and dispersion of the temperature. Thus, the operating principle of GC substance into that relatively large volume can be distinguished as either gas–solid chro- resulted in reduced efficiency. Thus the effi- matography (mainly an adsorptive process by ciency of separations became limited by the the stationary phase) or gas–liquid chromatog- geometry of the detector, and not by its intrinsic raphy (GLC; mainly partition of the analytes sensitivity. Detector design was modified to between the mobile and stationary phases), incorporate smaller tube dimensions, and the based on the physical characteristics of the volume of the sensing cell was thereby reduced stationary phase. Capillary columns, introduced greatly. The introduction of capillary columns in the early 1980s, have now replaced packed suitable for routine use in GC in the mid-1980s columns for most applications. The original glass Gas chromatography 471 columns were fragile and have been superseded allows for more flexibility and greater durability by fused-silica capillary columns. Fused silica is and reduces the possibility of degradation of high-purity synthetic quartz, with a protective analytes which can be catalysed by the presence coating of polyimide applied to the outer of metal surfaces. surface. Since these columns retain their flexi- Both bonding and cross-linking impart bility only as long as the coating remains enhanced thermal and solvent stability to the undamaged, their operating temperature must stationary phase (often designated ‘DB’), and be maintained below 360ЊC for standard should be used if they are available. For con- columns (400ЊC for high-temperature polyimide ventional packed column chromatography, coatings). The first capillary columns were 0.2, however, the stationary phase must first be 0.25 or 0.32 mm internal diameter (i.d.) and coated onto the surface of a solid support. between 10 and 50 m long. Subsequently ‘mega- bore’ (0.53 mm i.d.), ‘minibore’ (0.18 mm i.d.) and ‘microbore’ (0.1 or 0.05 mm i.d.) columns Stationary phases and support materials have been developed. When coated with a heat- resistant polymer, these have the advantages of Solid stationary phases flexibility and strength, and can be threaded with ease through intricate pipework. A single In gas–solid chromatography, the stationary column can be fitted into almost any manufac- phase is an active solid at its operating tempera- turer’s GC apparatus. Capillary columns provide ture. A conventional packed column is filled improved resolution, sensitivity and durability, completely by stationary phase particles, but in a less bleed with increasing temperatures, and ease capillary column a fine layer (usually less than of maintenance and repair; they yield reliable 10 lm) of particles is adhered by proprietary and highly reproducible separations, typically processes to the inner surface of the tubing, to over many hundreds or thousands of injections. create a PLOT column. These solid phases may This has reduced the number of columns be inorganic materials (e.g. aluminium oxides, required to achieve a satisfactory separation of molecular sieves, silica gel, or graphitised quite complex mixtures. carbon), or they may be organic polymers The internal surface of the silica is deactivated such as styrene. Both packed and capillary by a variety of processes that can react silanol columns use similar solid-phase materials. groups (Si1OH) on the silica surface with a Sample compounds undergo a dynamic gas– silane reagent (usually a methyl or phenyl- solid adsorption–desorption process with the methyl surface is created). For gas–solid capillary stationary phase, and since the particles are chromatography, a fine layer (usually less than porous, size exclusion and shape selectivity 10 lm) of stationary phase particles is adhered to processes also occur. The carrier gas (mobile the tubing (porous layer open tubular columns, phase) merely serves to sweep towards the or PLOT columns). For gas–liquid capillary chro- detector those solute molecules that are not matography, the stationary phase may be coated currently adsorbed. The resultant columns are or covalently bonded directly onto the walls of highly retentive, and separations impossible the column (wall-coated open tubular columns, with liquid phases can be accomplished easily on or WCOT columns) or onto a support (e.g. PLOT columns above ambient temperature. microcrystals of sodium or barium chloride) These columns are generally reserved for the bonded to the column wall (support-coated separation of low-molecular-weight materials, open tubular columns, or SCOT columns). such as hydrocarbon and sulfur gases, noble and Stainless-steel capillaries are usually reserved for permanent gases, and low boiling solvents. Since applications that require extremes of tempera- PLOT columns occasionally shed particles, their ture, or where the possibility of column breakage use is not advised with detectors that are affected cannot be tolerated. Nowadays, the internal adversely by the intrusion of particulate matter surface of metal columns is specially deactivated (the mass spectrometer is particularly vulnerable, chemically or by lining with fused silica, which as the column interface operates under vacuum). 472 Clarke’s Analytical Forensic Toxicology Graphitised carbon black methanol to pentanol. Tenax-TA is a porous Carbopaks are graphitised carbon black, having polymer of 2,6-diphenyl-p-phenylene oxide, adsorptive surfaces of up to 100 m2/g. They are used both as a chromatographic phase and as a usually modified with a light coating of a polar trap for volatile substances prior to analysis. It is stationary phase. Difficult separations of the C1 also used for high-boiling alcohols, polyethylene to C10 hydrocarbons can be achieved rapidly. glycols (PEGs), phenols, aldehydes, ketones, Carbopak C with 0.2% Carbowax 20M has been ethanolamines and chlorinated aromatics.
Recommended publications
  • Did Internet-Purchased Diet Pills Cause Serotonin Syndrome?
    Did Internet-purchased diet pills cause serotonin syndrome? Phentermine also may have increased patient’s neuroleptic malignant syndrome risk s. G, age 28, presents to a tertiary® careDowden hospital Health Media with altered mental status. Six weeks ago she Mstarted taking phentermine, 37.5 mg/d, to lose weight. Her body mass indexCopyright is 24 kg/mFor2 (normal personal range), use only and she obtained the stimulant agent via the Internet. Her family reports Ms. G was very busy in the past week, staying up until 2 AM cleaning. They say she also was irritable with her 5-year-old son. Two days ago, Ms. G complained of fatigue and nausea without emesis. She went to bed early and did not awaken the next morning. Her sister found her in bed, minimally re- DIONISI sponsive to verbal stimuli, and brought her to the hospital. Patients have used phentermine as a weight-reducing IMAGES/SANDRA GETTY agent since the FDA approved this amphetamine-like © compound in 1960.1 Phentermine’s mechanism of ac- tion is thought to involve dopaminergic, noradrenergic, Kyoung Bin Im, MD and serotonergic effects.2 Stimulation of norepineph- Chief resident Internal medicine and psychiatry combined residency program rine (NE) release is its most potent effect, followed Departments of internal medicine and psychiatry by NE reuptake inhibition, stimulation of dopamine Jess G. Fiedorowicz, MD (DA) release, DA reuptake inhibition, stimulation of Associate in psychiatry serotonin (5-HT) release, and 5-HT reuptake inhibition Department of psychiatry (weak).3 Roy J. and Lucille A. Carver College of Medicine Because phentermine could in theory cause serotonin 4 University of Iowa syndrome, its use is contraindicated with monoamine Iowa City oxidase inhibitors (MAOIs) and not recommended with selective serotonin reuptake inhibitors (SSRIs).5 One case report describes an interaction between fl uox- etine and phentermine that appears consistent with se- rotonin syndrome.6 We are aware of no case reports of Current Psychiatry serotonin syndrome caused by phentermine alone.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • The Effects of Aminorex and Related Compounds on Brain Monoamines and Metabolites in CBA Mice
    I p_._rmPharmac0l. 1997, 49:89-96 © 1997 J. Phann. Pharmacol. ._, A R_ce;vedMr.,' 29, 1996 AcceptedJuly 4, 1996 The Effects of Aminorex and Related Compounds on Brain Monoamines and Metabolites in CBA Mice YIWEN ZHENO, BRUCE RUSSELL, DAVID SCHMIERER* AND RICHARDLAVERTY Department of Pharmacology and *School of Pharmacy, University of Otago, P.O. Box 913, Dunedin, New Zealand Abstract Acute and long-term neurochemical effects of aminorex, an appetite-suppressing drug related to amphetamine in chemical structure, and stereoisomers of its analogues were examined and compared with those of 3,4- methylenedioxymethylamphetamine (MDMA) and fenfluramine. Aminorex and its analogues, with exception of 4S, 5S-dimethylaminorex, did not cause the long-term neurotransmitter depletion in either the dopaminergic or 5-HT-ergic systems that was observed after MDMA or fenfluramine in CBA mice. These results are discussed in terms of possible structurally related mechanisms of neurotoxicity. The acute neurochemical effects showed that aminorex and analogues all produced increases in 5- hydroxytryptamine (5-HT) levels, unlike fenfiuramine and MDMA in the present study or in published data. This suggests that inhibition of 5-HT metabolism, rather than direct 5-HT release, may be involved in their anorectic effect. The parallel study of acute doparnine and 3,4-dihydroxyphenylacetic acid (DOPAC) changes suggest that in CBA mice MDMA may he a better doparnine releaser and this may contribute to its dopaminergic neurotoxicity. However the ability to release doparnine or 5-HT, or both, may be important, but not the only factor involved in causing the long-term neurotoxicity observed with amphetamine derivatives.
    [Show full text]
  • Annex 2B Tariff Schedule of the United States See General Notes to Annex 2B for Staging Explanation HTSUS No
    Annex 2B Tariff Schedule of the United States See General Notes to Annex 2B for Staging Explanation HTSUS No. Description Base Rate Staging 0101 Live horses, asses, mules and hinnies: 0101.10.00 -Purebred breeding animals Free E 0101.90 -Other: 0101.90.10 --Horses Free E 0101.90.20 --Asses 6.8% B --Mules and hinnies: 0101.90.30 ---Imported for immediate slaughter Free E 0101.90.40 ---Other 4.5% A 0102 Live bovine animals: 0102.10.00 -Purebred breeding animals Free E 0102.90 -Other: 0102.90.20 --Cows imported specially for dairy purposes Free E 0102.90.40 --Other 1 cent/kg A 0103 Live swine: 0103.10.00 -Purebred breeding animals Free E -Other: 0103.91.00 --Weighing less than 50 kg each Free E 0103.92.00 --Weighing 50 kg or more each Free E 0104 Live sheep and goats: 0104.10.00 -Sheep Free E 0104.20.00 -Goats 68 cents/head A 0105 Live poultry of the following kinds: Chickens, ducks, geese, turkeys and guineas: -Weighing not more than 185 g: 0105.11.00 --Chickens 0.9 cents each A 0105.12.00 --Turkeys 0.9 cents each A 0105.19.00 --Other 0.9 cents each A -Other: 0105.92.00 --Chickens, weighing not more than 2,000 g 2 cents/kg A 0105.93.00 --Chickens, weighing more than 2,000 g 2 cents/kg A 0105.99.00 --Other 2 cents/kg A 0106 Other live animals: -Mammals: 0106.11.00 --Primates Free E 0106.12.00 --Whales, dolphins and porpoises (mammals of the order Cetacea); manatees and dugongs (mammals of the order Sirenia) Free E 0106.19 --Other: 2B-Schedule-1 HTSUS No.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • Introduced B.,Byhansen, 16
    LB301 LB301 2021 2021 LEGISLATURE OF NEBRASKA ONE HUNDRED SEVENTH LEGISLATURE FIRST SESSION LEGISLATIVE BILL 301 Introduced by Hansen, B., 16. Read first time January 12, 2021 Committee: Judiciary 1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to 2 amend sections 28-401, 28-405, and 28-416, Revised Statutes 3 Cumulative Supplement, 2020; to redefine terms; to change drug 4 schedules and adopt federal drug provisions; to change a penalty 5 provision; and to repeal the original sections. 6 Be it enacted by the people of the State of Nebraska, -1- LB301 LB301 2021 2021 1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2 2020, is amended to read: 3 28-401 As used in the Uniform Controlled Substances Act, unless the 4 context otherwise requires: 5 (1) Administer means to directly apply a controlled substance by 6 injection, inhalation, ingestion, or any other means to the body of a 7 patient or research subject; 8 (2) Agent means an authorized person who acts on behalf of or at the 9 direction of another person but does not include a common or contract 10 carrier, public warehouse keeper, or employee of a carrier or warehouse 11 keeper; 12 (3) Administration means the Drug Enforcement Administration of the 13 United States Department of Justice; 14 (4) Controlled substance means a drug, biological, substance, or 15 immediate precursor in Schedules I through V of section 28-405. 16 Controlled substance does not include distilled spirits, wine, malt 17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance 18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
    [Show full text]
  • Schedules of Controlled Substances (.Pdf)
    PURSUANT TO THE TEXAS CONTROLLED SUBSTANCES ACT, HEALTH AND SAFETY CODE, CHAPTER 481, THESE SCHEDULES SUPERCEDE PREVIOUS SCHEDULES AND CONTAIN THE MOST CURRENT VERSION OF THE SCHEDULES OF ALL CONTROLLED SUBSTANCES FROM THE PREVIOUS SCHEDULES AND MODIFICATIONS. This annual publication of the Texas Schedules of Controlled Substances was signed by John Hellerstedt, M.D., Commissioner of Health, and will take effect 21 days following publication of this notice in the Texas Register. Changes to the schedules are designated by an asterisk (*). Additional information can be obtained by contacting the Department of State Health Services, Drugs and Medical Devices Unit, P.O. Box 149347, Austin, Texas 78714-9347. The telephone number is (512) 834-6755 and the website address is http://www.dshs.texas.gov/dmd. SCHEDULES Nomenclature: Controlled substances listed in these schedules are included by whatever official, common, usual, chemical, or trade name they may be designated. SCHEDULE I Schedule I consists of: -Schedule I opiates The following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, if the existence of these isomers, esters, ethers, and salts are possible within the specific chemical designation: (1) Acetyl-α-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide); (2) Acetylmethadol; (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide); (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide) (Other name:
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Effect of Phenmetrazine, Aminorex and (+)P-Chloramphetamine on The
    Br. J. Pharmac. (1971), 43, 570-579. Effect of phenmetrazine, aminorex and (+) p-chloramphetamine on the motor activity and turnover rate of brain catecholamines E. COSTA, K. M. NAIMZADA* AND A. REVUELTA Laboratory of Preclinical Pharmacology, National Institute of Mental Health, Saint Elizabeth's Hospital, Washington, DC 20032, USA Summary 1. The minimal doses (umol/kg i.v.) of phenmetrazine, (±)-p-chloramphet- amine, and aminorex which increase motor activity are 5 6, 3 5, and 1-5, respec- tively. We detected stereotype behaviour neither in rats receiving intravenous doses 3 times greater nor in animals injected intraperitoneally with 44, 62 and 112 tumol/kg of (±)-p-chloramphetamine, aminorex and phenmatrazine, respectively. 2. The latter doses of the three amphetamine congeners were tested for their action on tissue monoamine content. Only (± )-p-chloramphetamine decreased the concentration of tel-diencephalon 5-hydroxytryptamine (5-HT) and this decrease lasted longer than 24 hours. This and the other two amphetamine congeners failed to affect the concentration of noradrenaline (NA) in brain, heart and lung. 3. Aminorex (1P5 mol/kg i.v.) and (±)-p-chloramphetamine (35 ,umol/kg i.v.) decreased the turnover time of striatum dopamine (DM) but failed to change the turnover time of tel-diencephalon and brainstem NA. Phenmetrazine (5-6 tumol/kg i.v.) changed neither the turnover time of striatum DM nor that of NA in the two brain areas assayed. Introduction Release of neuronal noradrenaline (NA) mediates many actions of (+)-amphet- amine, including psychomotor stimulation (Trendelenburg, Muskus, Flemming & Alonso de la Sierra, 1962; Stein, 1964; Rech, 1964; Weissman, Koe & Tenen, 1966; Sulser, Owens, Norvich & Dingell, 1968; Rech & Stalk, 1970).
    [Show full text]
  • Laws 2021, LB236, § 4
    LB236 LB236 2021 2021 LEGISLATIVE BILL 236 Approved by the Governor May 26, 2021 Introduced by Brewer, 43; Clements, 2; Erdman, 47; Slama, 1; Lindstrom, 18; Murman, 38; Halloran, 33; Hansen, B., 16; McDonnell, 5; Briese, 41; Lowe, 37; Groene, 42; Sanders, 45; Bostelman, 23; Albrecht, 17; Dorn, 30; Linehan, 39; Friesen, 34; Aguilar, 35; Gragert, 40; Kolterman, 24; Williams, 36; Brandt, 32. A BILL FOR AN ACT relating to law; to amend sections 28-1202 and 69-2436, Reissue Revised Statutes of Nebraska, and sections 28-401 and 28-405, Revised Statutes Cumulative Supplement, 2020; to redefine terms, change drug schedules, and adopt federal drug provisions under the Uniform Controlled Substances Act; to provide an exception to the offense of carrying a concealed weapon as prescribed; to define a term; to change provisions relating to renewal of a permit to carry a concealed handgun; to provide a duty for the Nebraska State Patrol; to eliminate an obsolete provision; to harmonize provisions; and to repeal the original sections. Be it enacted by the people of the State of Nebraska, Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2020, is amended to read: 28-401 As used in the Uniform Controlled Substances Act, unless the context otherwise requires: (1) Administer means to directly apply a controlled substance by injection, inhalation, ingestion, or any other means to the body of a patient or research subject; (2) Agent means an authorized person who acts on behalf of or at the direction of another person but does not include a common or contract carrier, public warehouse keeper, or employee of a carrier or warehouse keeper; (3) Administration means the Drug Enforcement Administration of the United States Department of Justice; (4) Controlled substance means a drug, biological, substance, or immediate precursor in Schedules I through V of section 28-405.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,101,661 B2 Mickle (45) Date of Patent: *Jan
    USOO81 01661 B2 (12) United States Patent (10) Patent No.: US 8,101,661 B2 Mickle (45) Date of Patent: *Jan. 24, 2012 (54) POLAR HYDROPHILIC PRODRUGS AND W 388-39. 358. NON-STANDARDAMNO ACID CONUGATES OF AMPHETAMINE AND WO 2008/098151 8, 2008 OTHER STIMULANTS AND PROCESSES FOR OTHER PUBLICATIONS MAKING AND USING THE SAME European Patent Office, Communication dated Jun. 8, 2010, in EP Application No. 07869 098.9. (75) Inventor: Travis C. Mickle, Coralville, IA (US) Amy Sorter, Understanding ADHD Stimulant Abuse, Publication, Vitality Drug Free Work, 2002. (http://12.42.224.168/HealthyLiv (73) Assignee: KemPharm, Inc., North Libery, IA (US) ing family homeljan04 family homestimulantabuse.htm). International Preliminary Report on Patentability for PCT Interna (*) Notice: Subject to any disclaimer, the term of this tional Application No. PCT/US08/53363, dated Nov. 6, 2008. Davankova et al., “Synthesis and Pharmacological Properties of N patent is extended or adjusted under 35 Aminoacyl Derivatives of Beta Phenyl ISO Propylamine.” Pharma U.S.C. 154(b) by 0 days. ceutical Chemistry Journal, vol. 9, No. 3, 1975. G.C. Barrett, D.T. Elmore; Methods for Peptide Bonds Amino Acids This patent is Subject to a terminal dis and Peptides; 1st Edition, Cambridge University Press, UK, 1998, pp. claimer. 151-156. International Search Report and Written Opinion corresponding to (21) Appl. No.: 12/843,169 International Application Serial No. PCT/US08/53363, mailed Nov. 6, 2008, 19 pages. (22) Filed: Jul. 26, 2010 J. Jones; Amino Acid and Peptide Synthesis; 2nd Edition, Oxford University Press, UK, 2002, pp. 25-41.
    [Show full text]